ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESR01

Eliminating the latent reservoir by targeted in vivo delivery of HIV-specific CARs

Active
Institution
University of Pennsylvania, PA
Principal investigator
James L. Riley
Funding
$759K
Duration
2023–2028
Open portfolio

Moonbase score

Still being scored

Abstract

Project Summary For HIV cure approaches to be widely implemented, they will need to be safe, affordable and highly effective. The development strategies that allow therapeutic agents to be infused into people living with HIV (PLWH) rather than being manufactured ex vivo may represent an important step to reaching this goal. In this application, the investigators merged their expertise in mRNA lipid nanoparticles (mRNA-LNPs) and HIV CAR technology to propose to develop injectable agents that will target and remove the latent reservoir. A key advantage of this approach is that we can target tissues and cells such as the reproductive track or T follicular cells where CTLs are either excluded or have diminished activity. In Aim 1, we will optimize the composition of these mRNA-LNPs performing in vitro studies. Once lead compounds are identified, we will test these in humanized mouse for in vivo activity. Finally, using a state of the art non-human primate model we will test the ability of mRNA-LNP complexes to reduce the viral reservoir.

Research team

  • Hamideh ParhizPI
  • James L. RileyPI

LOADING MOONBASE SCORE

R01NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESZAI1-LK-A(S2)mergedlipid nanoparticlesviral reservoirreservoirlatentctlshiv-specifichiv

Questions for University of Pennsylvania

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.